Proposed trials in brief
1. Septic Shock Clinical Trial – Our Target is £1.5 to £2 million
Sepsis/Septic shock is the 3rd leading cause of death in the developed world.
Please help us to raise money for a patient trial to test very high doses of intravenous vitamin B12 / Cobalamin in the treatment of septic shock.
Septic Shock and Cancer
Cancer sufferers are particularly vulnerable to sepsis and septic shock, because their immune systems are badly weakened by chemotherapy. It is estimated that 67% of cancer patients die from infections brought on by a ravaged immune system. Post-operative and transplant patients, the old and the very young are also very susceptible.
What is septic shock?
Septic shock kills at least 50% of its victims.
It happens when the body is overtaken by infection. The circulation fails, the organs collapse and the person can die.
Who gets it?
Examples include children with meningitis, old people with pneumonia, 67% of cancer patients, AIDS patients, transplant patients, accident victims and patients contracting the hospital super-bug MRSA. Avian flu can also result in septic shock.
Why should we fund this trial?
- Animal trials going back half a century testing B12 / Cobalamin in the treatment of septic shock have shown that it works.
- Vitamin B12 / Cobalamin has a supremely good safety record – in France they use mega doses to treat cyanide poisoning.
- Despite the use of antibiotics, there is currently no successful treatment for septic shock.
- Drug companies will never fund this trial – there is no commercial value to them, as vitamins are not patentable.
- We are now in collaboration with the highly respected William Harvey Institute, London, where successful pre-clinical lab studies have recently supported Dr Wheatley’s hypothesis.
- If successful, we would have a cheap treatment which will have worldwide implications for healthcare costs and, quite simply, human life.
The History to this project:
Dr Carmen Wheatley set up Survive Cancer in 1999 to promote an integrated approach to cancer treatment. We believe that it is basic commonsense to boost the overall health of your body’s immune system when you are ill, using vitamins, minerals, herbs and other natural therapies – known as orthomolecular medicine – especially when you are undergoing chemo and radio-therapy.
During her research into orthomolecular solutions to disease, Carmen found successful animal studies testing vitamin B12 / Cobalamin in the treatment of septic and traumatic shock.
Since publication of Dr Wheatley’s 3 papers on the use of vitamin B12 / Cobalamin in the treatment of septic shock, her hypothesis has attracted international interest from scientists in the field of inflammation. Professors from Harvard, London and Milan have offered to collaborate. We have recently completed the first round of preliminary lab studies at the William Harvey Institute, London, conducted by Professor Mauro Perretti and his colleagues Professor Fulvio D`Acquisto and Dr Andre Sampaio. The results are very exciting, and support Dr Wheatley’s hypothesis.
Why this is exciting:
Rigorous patient trials are essential if we are to test new approaches to disease. Now we have a chance to do just this, with a vitamin that has been proved to have an excellent safety record in high doses, to treat a life-threatening condition which conventional medicine has so far failed to cure. We have the attention of serious, internationally renowned scientists and doctors, eager to test, yes, a vitamin! If it works, it will be a life-saver for millions – perhaps even you!
2. MGUS/Multiple Myeloma Clinical Trial
Please help us to raise money for a small patient trial to test very high doses of vitamin B12 in the treatment of MGUS.
OUR TARGET IS £100,000
This small patient trial will test Dr Carmen Wheatley’s other published hypothesis, that high doses of vitamin B12 can be used in the successful treatment of MGUS, the pre-cancer stage, from which 1 out of 4 patients can be expected to progress to Multiple Myeloma, or other related conditions, such as Waldenstrom’s, Chronic Lymphocytic Leukaemia, Myelodysplastic Syndrome, Macroglobulinaemia, Myelofibrosis, Polycythaemia/Vera/Rubra, Essential Thrombocythaemia, and certain lymphomas, such as Lymphocytic Lymphoma.
If and when the money is in place and we have the go ahead, anyone wishing to take part in the trial will be able to contact the participating hospital nearest to them. If you wish us to contact you directly about this, please leave your details in the `Contact Form’ on the left hand side of this page. We have published the current protocol on the website, (which may be revised before the trial takes place), and we will keep you informed on this site about our progress in setting up the trial.
Depending on the results of this patient trial to test vitamin B12 in the treatment of MGUS, Survive Cancer plans to do a follow-up trial to test vitamin B12 in the treatment of Multiple Myeloma.